FIELD: medicine.
SUBSTANCE: invention refers to medical chemistry and oncology. Disclosed is the use of gold polyacrylate (polyacrylic acid polymer containing gold (III) ions) as a cytotoxic agent for chemotherapy of melanoma. It is suggested that gold polyacrylate will be in demand for treating melanoma and preventing development of its resistance to chemotherapeutic agents.
EFFECT: gold polyacrylate has high specific activity on human and mouse melanoma cells with significantly lower acute toxicity (that is a wide therapeutic index) as compared to Cisplatin – the chemically closest commercially applicable cytostatic agent recommended for melanoma therapy.
1 cl, 2 tbl, 4 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF PRODUCING GOLD POLYACRYLATE EXHIBITING ANTI-TUMOR ACTIVITY | 2018 |
|
RU2690536C1 |
| DI[(FURAN-3-CARBOXYLATE-O)-(2,9-DIMETHYL-1,10-PHENANTHROLINE-N,N')-COPPER(II)] WITH ANTIPROLIFERATIVE AND ANTIMYCOBACTERIAL ACTIVITY | 2023 |
|
RU2815425C1 |
| ANTITUMOUR AGENT, RELATED TO GROUP OF METAL-ORGANIC DERIVATIVES OF POLYACRYLIC ACID | 2008 |
|
RU2372091C1 |
| AGENTS SUPPRESSING PROLIFERATION OF CANCER CELLS | 1993 |
|
RU2098096C1 |
| METHOD FOR TUMOUR GROWTH INHIBITION | 2012 |
|
RU2491930C1 |
| BRAF KINASE INHIBITOR N-(3-(5-(4-CHLOROPHENYL)-1H-PYRAZOLO[3,4-B]PYRIDIN-3-CARBONIL)-2,4-DIFLUOROPHENYL)PROPANE-1-SULFONAMIDE | 2018 |
|
RU2687107C1 |
| N-(3-(5-(4-CHLOROPHENYL)-1N-PYRAZOLO[3,4-B]PYRIDINE-3-CARBONYL)-2,4-DIFLUOROPHENYL)PROPANE-1-SULPHONAMIDE CRYSTALLINE FORM, ACTIVE COMPONENT, PHARMACEUTICAL COMPOSITION AND MEDICINE | 2018 |
|
RU2678455C1 |
| COMBINED THERAPY PAC-1 | 2016 |
|
RU2720509C2 |
| POLYMER CONTAINING MEDICINAL AGENT BASED ON ANTITUMOR AGENT ETOPOSIDE | 2015 |
|
RU2595859C1 |
| COMBINATION AND METHODS FOR INTRODUCING THERAPEUTIC AGENTS AND COMBINED THERAPY | 2006 |
|
RU2452482C2 |
